trending Market Intelligence /marketintelligence/en/news-insights/trending/tl7j7Sm6EuxvJNsSQD_-fA2 content esgSubNav
In This List

INSYS Therapeutics' cannabis treatment receives US FDA's fast track designation

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


INSYS Therapeutics' cannabis treatment receives US FDA's fast track designation

INSYS Therapeutics Inc.'s cannabis treatment to treat the Prader-Willi syndrome received the U.S. Food and Drug Administration's fast track designation.

Prader-Willi syndrome is a rare genetic disorder characterized by insatiable appetite in children that often leads to obesity and type 2 diabetes.

The company plans to start clinical development of its oral investigational treatment in the late first quarter of 2018.